Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Lopes

Showing results (141-150 of 177) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|April 9, 2019
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony S K Mok, Yi-Long Wu, Iveta Kudaba, et al.
Orphanet Journal of Rare Diseases|September 17, 2014
A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific regionSwee-Sung Soon, Gilberto Lopes, Hwee-Yong Lim, et al.
Journal of Global Oncology|December 28, 2017
Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in BrazilPaulo G Bergerot, Cristiane D Bergerot, Nazli Dizman, et al.
Frontiers in Oncology|September 13, 2023
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancerRobert Hsu, Denaly Chen, Bing Xia, et al.
Nature Medicine|August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trialVivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Diabetes Research and Clinical Practice|March 15, 2023
Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trialsBernardo F Spiazzi, Rafaella A Naibo, Laura F Wayerbacher, et al.
Diabetes, Obesity & Metabolism|February 23, 2024
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysisLeonardo A Mesquita, Bernardo F Spiazzi, Giovana F Piccoli, et al.
JCO Global Oncology|March 26, 2026
Exercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey StudyPaulo Gustavo Bergerot, Cristiane Decat Bergerot, Errol J Philip, et al.
Lancet (London, England)|November 6, 2016
Changing global policy to deliver safe, equitable, and affordable care for women's cancersOphira Ginsburg, Rajan Badwe, Peter Boyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Iveta Kudaba, Yi-Long Wu, et al.
Pageof 18

Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|April 9, 2019
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony S K Mok, Yi-Long Wu, Iveta Kudaba, et al.
Orphanet Journal of Rare Diseases|September 17, 2014
A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific regionSwee-Sung Soon, Gilberto Lopes, Hwee-Yong Lim, et al.
Journal of Global Oncology|December 28, 2017
Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in BrazilPaulo G Bergerot, Cristiane D Bergerot, Nazli Dizman, et al.
Frontiers in Oncology|September 13, 2023
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancerRobert Hsu, Denaly Chen, Bing Xia, et al.
Nature Medicine|August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trialVivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Diabetes Research and Clinical Practice|March 15, 2023
Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trialsBernardo F Spiazzi, Rafaella A Naibo, Laura F Wayerbacher, et al.
Diabetes, Obesity & Metabolism|February 23, 2024
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysisLeonardo A Mesquita, Bernardo F Spiazzi, Giovana F Piccoli, et al.
JCO Global Oncology|March 26, 2026
Exercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey StudyPaulo Gustavo Bergerot, Cristiane Decat Bergerot, Errol J Philip, et al.
Lancet (London, England)|November 6, 2016
Changing global policy to deliver safe, equitable, and affordable care for women's cancersOphira Ginsburg, Rajan Badwe, Peter Boyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Iveta Kudaba, Yi-Long Wu, et al.
Pageof 18